BCAB Bioatla Inc

USD 1.80 0.00 0
Icon

Bioatla Inc (BCAB) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 1.80

0.00 (0.00)%

USD 0.09B

0.89M

USD 7.75(+330.56%)

USD 3.50 (+94.44%)

Icon

BCAB

Bioatla Inc (USD)
COMMON STOCK | NSD
USD 1.80
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 0.09B

USD 3.50 (+94.44%)

USD 1.80

Bioatla Inc (BCAB) Stock Forecast

Show ratings and price targets of :
USD 7.75
(+330.56%)

Based on the Bioatla Inc stock forecast from 2 analysts, the average analyst target price for Bioatla Inc is USD 7.75 over the next 12 months. Bioatla Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bioatla Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Bioatla Inc’s stock price was USD 1.80. Bioatla Inc’s stock price has changed by +36.36% over the past week, +14.65% over the past month and -35.71% over the last year.

No recent analyst target price found for Bioatla Inc
No recent average analyst rating found for Bioatla Inc

Company Overview Bioatla Inc

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologi...Read More

https://www.bioatla.com

11085 Torreyana Road, San Diego, CA, United States, 92121

65

December

USD

USA

Adjusted Closing Price for Bioatla Inc (BCAB)

Loading...

Unadjusted Closing Price for Bioatla Inc (BCAB)

Loading...

Share Trading Volume for Bioatla Inc Shares

Loading...

Compare Performance of Bioatla Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BCAB

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Bioatla Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD127.00B 31.94 20.00

ETFs Containing BCAB

Symbol Name BCAB's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Bioatla Inc (BCAB) Stock

Based on ratings from 2 analysts Bioatla Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.

Unfortunately we do not have enough data on BCAB's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for BCAB is USD 7.75 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 5.

Unfortunately we do not have enough data on BCAB's stock to indicate if its overvalued.

The last closing price of BCAB's stock was USD 1.80.

The most recent market capitalization for BCAB is USD 0.09B.

Based on targets from 2 analysts, the average taret price for BCAB is projected at USD 7.75 over the next 12 months. This means that BCAB's stock price may go up by +330.56% over the next 12 months.

We can't find any ETFs which contains Bioatla Inc's stock.

As per our most recent records Bioatla Inc has 65 Employees.

Bioatla Inc's registered address is 11085 Torreyana Road, San Diego, CA, United States, 92121. You can get more information about it from Bioatla Inc's website at https://www.bioatla.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...